Director, Regulatory CMC

Associate Director, Analytical Development & Quality Control

Scientist, Discovery

Senior Scientist, Drug Substance

Director, Program Management, Drug Development

1910 Genetics

20n Bio

3DBio Therapeutics

3T Biosciences

4D Molecular Therapeutics

64x Bio

76Bio

8Biomed

A-Alpha Bio

A2 Biotherapeutics

AavantiBio

Ab Studio

Abalone Bio

Abata Therapeutics

Abeona Therapeutics

Abintus Bio

Abiosciences

Absci

Accelevir Diagnostics

Accent Therapeutics

ACELYRIN

Acepodia

Achieve Life Sciences

Acrivon Therapeutics

Acutis Diagnostics

Adaptive Phage Therapeutics

Adcentrx Therapeutics

Adicet Bio

Aditum Bio

adMare BioInnovations

Admera Health

Adverum Biotechnologies

adyn

Aeglea BioTherapeutics

Aether Bio

Affini-T Therapeutics

Affinia Therapeutics

Affinivax

AgBiome

Agena Bioscience

AIRNA Bio

Akero Therapeutics

Akouos

Alamar Biosciences

Alector

AlivaMab Discovery Services

Alkahest

Alladapt Immunotherapeutics

Allakos

Allarta Life Science

Allay Therapeutics

AlloVir

Alloy Therapeutics

Alltrna

AlpaLifeBio

Alpha-9 Theranostics

Alphabioregen

Alpine Immune Sciences

Altis Biosystems

Alto Neuroscience

AltPep

Alumis

Alveo Technologies

Alveolus Bio

ALX Oncology

Alzheon

AmbAgon Therapeutics

Amberstone Biosciences

Amolyt Pharma

Amylyx Pharmaceuticals

AN2 Therapeutics

Anagram Therapeutics

Andes

Angiex

Angiocrine Bioscience

AnHeart Therapeutics

Annexon Biosciences

Anokion

Ansa Biotechnologies

Antheia

Anthos Therapeutics

AOA Dx

Apic Bio

Apollomics

Appia Bio

Applied Molecular Transport

Apriori Bio

Aptevo Therapeutics

Apton Biosystems

Aptose Biosciences

Aquinnah Pharmaceuticals

Aramis Biosciences

Arbor Biotechnologies

Arcadia Science

Arcellx

Arctoris

Arcturus Therapeutics

Arcutis Biotherapeutics

Arima Genomics

Ark Biotech

PepGen Therapeutics is creating the next generation of oligonucleotide therapies to transform treatments of neuromuscular diseases. Oligonucleotides delivered into cells can modulate RNA expression to treat disease. PepGen is using their proprietary Enhanced Delivery Oligonucleotide (EDO) platform to identify cell-penetrating peptide conjugates that improve the activity and tolerability of oligonucleotide cargo therapeutics. PepGen’s proprietary EDO peptides are engineered for optimal tissue and cell penetration and have been shown to transport oligonucleotides into many target tissues including skeletal and cardiac muscle. PepGen is generating a pipeline of oligonucleotide therapies that target the root cause of serious neuromuscular diseases.

<p>PepGen Therapeutics is creating the next generation of oligonucleotide therapies to transform treatments of neuromuscular diseases. Oligonucleotides delivered into cells can modulate RNA expression to treat disease. PepGen is using their proprietary Enhanced Delivery Oligonucleotide (EDO) platform to identify cell-penetrating peptide conjugates that improve the activity and tolerability of oligonucleotide cargo therapeutics. PepGen’s proprietary EDO peptides are engineered for optimal tissue and cell penetration and have been shown to transport oligonucleotides into many target tissues including skeletal and cardiac muscle. PepGen is generating a pipeline of oligonucleotide therapies that target the root cause of serious neuromuscular diseases.</p>


Find a biotech startup job.